Charles Osborne
Director of Finance/CFO at POLAREAN IMAGING PLC
Profile
Charles Fremont Osborne is currently the Chief Financial Officer & Director at Polarean Imaging Plc.
Previously, he held the position of Vice President-Finance at International Murex Technologies Corp.
From 2003 to 2015, he served as the Chief Financial Officer at SCYNEXIS, Inc. He also worked as the Chief Financial Officer at Nobex Corp.
In addition, he was the Chief Financial Officer & Secretary at Innocrin Pharmaceuticals, Inc. from 2015 to 2019.
Mr. Osborne obtained his undergraduate degree from The University of North Carolina at Charlotte in 1987.
Charles Osborne active positions
Companies | Position | Start |
---|---|---|
POLAREAN IMAGING PLC | Director of Finance/CFO | 29/04/2019 |
Former positions of Charles Osborne
Companies | Position | End |
---|---|---|
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Director of Finance/CFO | 01/04/2019 |
SCYNEXIS, INC. | Director of Finance/CFO | 30/06/2015 |
International Murex Technologies Corp.
International Murex Technologies Corp. Medical SpecialtiesHealth Technology International Murex Technologies Corp. develops medical diagnostic products. It provides infectious disease screening services. The company is headquartered in Norcross, GA. | Director of Finance/CFO | - |
Nobex Corp.
Nobex Corp. Pharmaceuticals: MajorHealth Technology Protein Delivery Inc. is drug delivery company. It specializes in proprietary polymer-based technology for the stabilization and oral delivery of proteins and peptides as well as the delivery of small molecules across the blood-brain barrier. The company's technology also enables the delivery of drugs into the brain to treat diseases of the central nervous system. Protein Delivery is located in Durham, NC | Director of Finance/CFO | - |
Training of Charles Osborne
The University of North Carolina at Charlotte | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
SCYNEXIS, INC. | Health Technology |
POLAREAN IMAGING PLC | Health Technology |
Private companies | 3 |
---|---|
Nobex Corp.
Nobex Corp. Pharmaceuticals: MajorHealth Technology Protein Delivery Inc. is drug delivery company. It specializes in proprietary polymer-based technology for the stabilization and oral delivery of proteins and peptides as well as the delivery of small molecules across the blood-brain barrier. The company's technology also enables the delivery of drugs into the brain to treat diseases of the central nervous system. Protein Delivery is located in Durham, NC | Health Technology |
International Murex Technologies Corp.
International Murex Technologies Corp. Medical SpecialtiesHealth Technology International Murex Technologies Corp. develops medical diagnostic products. It provides infectious disease screening services. The company is headquartered in Norcross, GA. | Health Technology |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Charles Osborne